Efficient neutralization of HIV is a primary goal both for therapeutic and prophylactic HIV vaccines based on induction of neutralizing antibodies (NAbs) ([@B1], [@B2]). Neutralization capacity of NAbs correlates with their affinity to HIV-1 gp120 envelope glycoprotein ([@B3]). In HIV-infected individuals, early IgM antibodies have low affinity for gp120 glycoprotein ([@B3]), which is slightly compensated by their pentameric structure and avidity to multivalent structures of the virus. Corresponding IgG1 antibodies ([@B3], [@B4]), which appear later from IgM through the CSR and SHM processes ([@B3], [@B5]), have high affinity and specificity to gp120, but low avidity due to monomeric structure of IgG. The question is how to induce HIV-specific NAbs with both high affinity and avidity to gp120?

Anti-HIV IgG antibodies 2F5 and 2G12, switched back to IgM isotype, showed increased avidity and neutralization efficacy ([@B2]). Dendritic antibody supramolecules (DAS) in one molecule combine high specificity of IgG with high avidity of IgM ([@B6]). It would be of interest to construct such a DAS with IgM as a core, carrying 10 anti-gp120 IgG monomers. Natural monomeric anti-gp120 IgG1 antibodies ([@B3], [@B4]) not only have low avidity insufficient for effective neutralization of HIV but may also contribute to FcR-mediated infection enhancement ([@B7], [@B8]). Does it mean that HIV may use high-affinity IgG antibodies for its own purposes? Fortunately, in nature there exist some helpful network-like regulatory mechanisms with a key role of RF antibodies ([@B9]).

Rheumatoid factor (RF) is an autoantibody which specifically binds Fc region of IgG ([@B10], [@B11]). Apart from pathologic RF in rheumatoid arthritis ([@B12]), natural RF appears in many non-rheumatoid states ([@B13]). Possible beneficial physiological roles of RF include enhanced clearance of immune complexes (ICs) ([@B14]), amplification of IgG response to pathogens ([@B15]), and enhancement of virus neutralization ([@B16], [@B17]). RF can be induced *in vivo* in a highly specific way either by secondary immunization with protein antigens or in response to immunization with the newly formed ICs ([@B10], [@B11]). New antigenic determinants, which appear in the Fc region of IgG antibody upon antibody-antigen complex formation, may strengthen the specificity of RF ([@B9]).

The level of RF was significantly higher in some of HIV-infected individuals compared to control groups ([@B18]--[@B22]). RFs were mainly IgA, IgM immunoglobulins with specificity against anti-HIV IgG ([@B20]). RF-mediated enhancement of anti-HIV IgG neutralization activity was found in the sera from MCTD patients ([@B17]). Authors suggested that RF is promising for passive immunotherapy based on NAbs ([@B17]).

Can RF play a key role in specific enhancement of IgG-mediated neutralization of HIV *in vivo*? Measurements of RF level both in long-term non-progressors ([@B23]) and dual-infected individuals ([@B24]) might give some clues. Repeated immunization of uninfected macaques with HIV-1 gp120 glycoprotein may allow researchers not only to track the kinetics of RF induction but also to elucidate whether neutralization-enhancing RF antibodies can protect macaques against subsequent challenge with SHIV. Repeated immunization of SHIV-infected macaques with HIV-1 gp120 glycoprotein might show whether neutralization-enhancing RF antibodies can prolong the asymptomatic period and delay the onset of AIDS.

The level of RF is not stable and has a tendency to decline during the acute phase of HIV infection ([@B22]). Prolonged repeated immunizations with gp120 (e.g., immunizations every 3 weeks; the actual time between immunizations will be adjusted according to measurements of RF level in patients) would be the solution to keep the level of neutralization-enhancing RF antibodies constantly high. Single-administration vaccine (SAV) technology, which is based on pulsatile release of gp120 from biodegradable polymeric microspheres, mimics repeated immunization scheme, and allows vaccination to be done in one shot ([@B25], [@B26]).

Patient-specific therapeutic HIV vaccines ([@B1]) even in simplified version, using the only one gp120 variant formed after completion of HIV population homogenization process ([@B27]), can be performed via repeated immunizations from biodegradable polymeric microspheres under SAV ([@B25], [@B26]) technology platform. Prophylactic HIV vaccines can be based on the variations of sequential scheme ([@B28]) for prolonged pulsatile release of gp120 glycoproteins from biodegradable polymeric microspheres in single-shot ([@B25], [@B26]) way convenient for both patients and doctors.

Studies ([@B15], [@B17]) have shown the high potential of neutralization-enhancing RF antibodies, but several principal questions arise: (i)Can neutralization-enhancing RF antibodies (NeRFa) be induced after repeated immunization of humans with recombinant gp120 glycoprotein?(ii)Will the power of gp120 immunogen design ([@B29]--[@B31]) combined with an optimal vaccination regimen help the induction of NeRFa?(iii)Could NeRFa help to improve the efficacy of previous ([@B32]) and future HIV vaccines based on induction of NAbs?(iv)Might induction of NeRFa be a future promising method not only against malaria as suggested in Ref. ([@B33]), but also against life-threatening viruses like Ebola ([@B34])?

Repeated immunization with gp120 glycoprotein might lead to prolonged induction of neutralization-enhancing RF antibodies with a potential to be explored for finding the ways to extend lives of HIV-infected individuals and to stop current HIV pandemic.
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